|
1
|
Sun J, Hu R, Han M, Tan Y, Xie M, Gao S
and Hu JF: Mechanisms underlying therapeutic resistance of tyrosine
kinase inhibitors in chronic myeloid leukemia. Int J Biol Sci.
20:175–181. 2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Arzoun H, Srinivasan M, Thangaraj SR,
Thomas SS and Mohammed L: The progression of chronic myeloid
leukemia to myeloid sarcoma: A systematic review. Cureus.
14(e21077)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zhou T, Medeiros LJ and Hu S: Chronic
myeloid leukemia: Beyond BCR-ABL1. Curr Hematol Malig Rep.
13:435–445. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Jabbour E and Kantarjian H: Chronic
myeloid leukemia: 2016 Update on diagnosis, therapy, and
monitoring. Am J Hematol. 91:252–265. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Stagno F, Stella S, Spitaleri A, Pennisi
MS, Di Raimondo F and Vigneri P: Imatinib mesylate in chronic
myeloid leukemia: Frontline treatment and long-term outcomes.
Expert Rev Anticancer Ther. 16:273–278. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kantarjian H, Sawyers C, Hochhaus A,
Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D,
Resta D, Capdeville R, Zoellner U, et al: Hematologic and
cytogenetic responses to imatinib mesylate in chronic myelogenous
leukemia. N Engl J Med. 346:645–652. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kaygusuz-Atagunduz I, Toptas T, Yumuk F,
Firatli-Tuglular T and Bayik M: Newly diagnosed breast cancer in a
patient receiving imatinib mesylate. J Cancer Res Ther.
10:1107–1108. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pan L, Duan J, Qiao W, Bi L, Wu D, Fan Z
and Yang M: Secondary breast carcinoma after completely remitted
chronic myeloid leukemia following targeted tyrosine kinase
inhibitor therapy. Breast Cancer. 24:790–793. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tanriverdi O, Unubol M, Taskin F, Meydan
N, Sargin G, Guney E and Barutca S: Imatinib-associated bilateral
gynecomastia and unilateral testicular hydrocele in male patient
with metastatic gastrointestinal stromal tumor: A literature
review. J Oncol Pharm Pract. 18:303–310. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Li N, Zhao L, Li J, Ding Y, Shen Y, Huang
X, Wang X and Wang J: Turner syndrome caused by rare complex
structural abnormalities involving chromosome X. Exp Ther Med.
14:2265–2270. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gala JL, Chenut F, Hong KB, Rodhain J,
Camby P, Philippe M and Scheiff JM: A panel of antibodies for the
immunostaining of Bouin's fixed bone marrow trephine biopsies. J
Clin Pathol. 50:521–524. 1997.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Narang NC, Rusia U, Sikka M and Kotru M:
Morphological changes in bone marrow post imatinib therapy in
chronic phase CML: A follow up study on sequential bone marrow
aspirates and Biopsies. J Clin Diagn Res. 11:EC25–EC29.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Xu YW and Duan MH: A unique bone marrow
lymphoma patient presenting with an isolated mass: A case report.
Oncol Lett. 15:2529–2533. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Al-Achkar W, Wafa A and Nweder MS: A
complex translocation t(5;9;22) in philadelphia cells involving the
short arm of chromosome 5 in a case of chronic myelogenous
leukemia. J Exp Clin Cancer Res. 26:411–415. 2007.PubMed/NCBI
|
|
15
|
Shaffer LG, Slovak ML and Campbell LJ
(eds): ISCN 2009: An international system for human cytogenetic
nomenclature. S. Karger, Basel, 2009.
|
|
16
|
Ewers E, Yoda K, Hamid AB, Weise A,
Manvelyan M and Liehr T: Centromere activity in dicentric small
supernumerary marker chromosomes. Chromosome Res. 18:555–562.
2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shen X, Zhang M, Shen Y, Shi W, Liu W and
Wei WU: Nilotinib rapidly reverses breakpoint cluster
region-Abelson oncogene fusion gene and M244V mutations in a
patient with chronic myelogenous leukemia: A case report. Exp Ther
Med. 10:1479–1482. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Syed NN, Usman M, Khaliq G, Adil SN and
Khurshid M: Clinico-pathologic features of chronic myeloid leukemia
and risk stratification according to Sokal score. J Coll Physicians
Surg Pak. 16:336–339. 2006.PubMed/NCBI
|
|
19
|
Leung AKC and Leung AAC: Gynecomastia in
infants, children, and adolescents. Recent Pat Endocr Metab Immune
Drug Discov. 10:127–137. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Karamchandani MM, De La Cruz Ku G, Sokol
BL, Chatterjee A and Homsy C: Management of gynecomastia and male
benign diseases. Surg Clin North Am. 102:989–1005. 2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kadivar A, Ibrahim Noordin M, Aditya A,
Kamalidehghan B, Davoudi ET, Sedghi R and Akbari Javar H:
Antiproliferative effects of imatinib mesylate on ZR-75-1 and
MDA-MB-231 cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF
expression. Int J Mol Med. 42:414–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ma Z, Zhao J, Li S, Gao F, Zhang C, Wu L
and Lin Y: Imatinib-induced ulcerative colitis. J Oncol Pharm
Pract: 10781552241255290, 2024 (Epub ahead of print).
|
|
23
|
Gupta P, Cherian KE, Kapoor N, Fouzia NA
and Paul TV: IM-induced gynecomastia. Indian J Endocrinol Metab.
23(648)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kim H, Chang HM, Ryu MH, Kim TW, Sohn HJ,
Kim SE, Kang HJ, Park S, Lee JS and Kang YK: Concurrent male
gynecomastia and testicular hydrocele after imatinib mesylate
treatment of a gastrointestinal stromal tumor. J Korean Med Sci.
20:512–515. 2005.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Liu H, Liao G and Yan Z: Gynecomastia
during imatinib mesylate treatment for gastrointestinal stromal
tumor: A rare adverse event. BMC Gastroenterol.
11(116)2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jain A, Varma S, Garg R and Malhotra P:
Unilateral gynaecomastia in a young man with chronic myeloid
leukemia. Indian J Hematol Blood Transfus. 33:448–450.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gambacorti-Passerini C, Tornaghi L,
Cavagnini F, Rossi P, Pecori-Giraldi F, Mariani L, Cambiaghi N,
Pogliani E, Corneo G and Gnessi L: Gynaecomastia in men with
chronic myeloid leukaemia after imatinib. Lancet. 361:1954–1956.
2003.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tavil B, Kınık S, Gözen A and Olcay L:
Gynecomastia in a boy with chronic myeloid leukemia during imatinib
therapy. Turk J Haematol. 30:336–337. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhao D, Wang G, Li C and Meng L: Bilateral
masculine mastoplasia associated with imatinib mesylate: A case
report and literature review. J Huazhong Univ Sci Technolog Med
Sci. 31:145–146. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Griffin J: The biology of signal
transduction inhibition: Basic science to novel therapies. Semin
Oncol. 28 (5 Suppl 17):S3–S8. 2001.PubMed/NCBI
|
|
31
|
Sette C, Dolci S, Geremia R and Rossi P:
The role of stem cell factor and of alternative c-kit gene products
in the establishment, maintenance and function of germ cells. Int J
Dev Biol. 44:599–608. 2000.PubMed/NCBI
|
|
32
|
Basciani S, Brama M, Mariani S, De Luca G,
Arizzi M, Vesci L, Pisano C, Dolci S, Spera G and Gnessi L:
Imatinib mesylate inhibits Leydig cell tumor growth: Evidence for
in vitro and in vivo activity. Cancer Res. 65:1897–1903.
2005.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ghalaut VS, Prakash G, Bansal P, Dahiya K,
Dokwal S, Ghalaut PS, Bala M and Dhankhar R: Effect of imatinib on
male reproductive hormones in BCR-ABL positive CML patients: A
preliminary report. J Oncol Pharm Pract. 20:243–248.
2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hou Z, Zhu HL and Liu T: Effects of
imatinib mesylate on the levels of endocrine hormones. Zhonghua Xue
Ye Xue Za Zhi. 34:762–766. 2013.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
35
|
Lindauer M and Hochhaus A: Dasatinib.
Recent Results Cancer Res. 212:29–68. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Caocci G, Atzeni S, Orrù N, Azzena L,
Martorana L, Littera R, Ledda A and La Nasa G: Gynecomastia in a
male after dasatinib treatment for chronic myeloid leukemia.
Leukemia. 22:2127–2128. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Prasetyono TOH, Andromeda I and
Budhipramono AG: Approach to gynecomastia and pseudogynecomastia
surgical techniques and its outcome: A systematic review. J Plast
Reconstr Aesthet Surg. 75:1704–1728. 2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
McLeod DG and Iversen P: Gynecomastia in
patients with prostate cancer: A review of treatment options.
Urology. 56:713–720. 2000.PubMed/NCBI View Article : Google Scholar
|
